Compare Mongodb Inc (MDB) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mongodb Inc vs Sanofi SA — how do they compare? Mongodb Inc trades at $386 (market cap $29.24B), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 3.3× Mongodb Inc's market cap, and Sanofi SA pays a 6.01% dividend while Mongodb Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mongodb Inc for 46 Days and Sanofi SA for 94 Days on average.
| MDB | SNY | |
|---|---|---|
Market Cap | $29.24B | $95.18B |
Volume | 1,304,995 | 2,995,646 |
Sector | Technology | Health |
52-Week High | $472.29 | $52.34 |
52-Week Low | $225.95 | $39.51 |
Typical Hold Time | 46 Days | 94 Days |
Enterprise Value | $26.86B | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MDB trades at $383.26, up 5.57% today, with a bullish technical signal and strong analyst support. The stock is near resistance at $384 after recent volatility from a CEO transition. Fundamentally, revenue growth is robust, reaching $2.01B in 2025, but profitability remains negative with a net loss of $129M. Recent Investor Day highlighted AI product launches and raised long-term targets, fueling optimism.
Outlook is positive with 80% analyst buy ratings and a $456.76 consensus target, but risks include persistent losses, high valuation multiples, and execution challenges amid leadership changes. The stock offers growth exposure to AI-driven database demand, yet investors must weigh profitability concerns against expansion potential.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
